Table 1.
Proportion of tumors upstaged by clinical or sociodemographic characteristics
| T-upstaging | N-upstaging | |||||||
|---|---|---|---|---|---|---|---|---|
| HR-positive | HR-negative | HR-positive | HR-negative | |||||
| Not Upstaged | Upstaged | Not Upstaged | Upstaged | Not Upstaged | Upstaged | Not Upstaged | Upstaged | |
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
| Total Upstaged | 75,639 (93.24) | 5,483 (6.76) | 8,262 (89.00) | 1,021 (11.00) | 70,824 (87.31) | 10,298 (12.69) | 8,285 (89.25) | 998 (10.75) |
| TTS (days) | ||||||||
| ≤ 30 | 43,055 (93.40) | 3,043 (6.60) | 4,977 (89.23) | 601 (10.77) | 40,249 (87.31) | 5,849 (12.69) | 4,975 (89.19) | 603 (10.81) |
| 31–60 | 27,885 (93.21) | 2,030 (6.79) | 2,822 (88.60) | 363 (11.40) | 26,158 (87.44) | 3,757 (12.56) | 2,858 (89.73) | 327 (10.27) |
| 61–90 | 3,869 (92.32) | 322 (7.68) | 383 (89.49) | 45 (10.51) | 3,649 (87.07) | 542 (12.93) | 375 (87.62) | 53 (12.38) |
| ≥ 91 | 830 (90.41) | 88 (9.59) | 80 (86.96) | 12 (13.04) | 768 (83.66) | 150 (16.34) | 77 (83.70) | 15 (16.30) |
| Age group | ||||||||
| ≤ 50 | 10,205 (91.29) | 974 (8.71) | 1,161 (84.50) | 213 (15.50) | 9,281 (83.02) | 1,898 (16.98) | 1,191 (86.68) | 183 (13.32) |
| > 50 | 65,434 (93.55) | 4,509 (6.45) | 7,101 (89.78) | 808 (10.22) | 61,543 (87.99) | 8,400 (12.01) | 7,094 (89.70) | 815 (10.30) |
| HER2 | ||||||||
| Negative | 68,763 (93.53) | 4,754 (6.47) | 6,655 (88.98) | 824 (11.02) | 64,324 (87.5) | 9,193 (12.50) | 6,734 (90.04) | 745 (9.96) |
| Borderline | 1,364 (91.30) | 130 (8.70) | 134 (88.16) | 18 (11.84) | 1,295 (86.68) | 199 (13.32) | 128 (84.21) | 24 (15.79) |
| Positive | 5,512 (90.20) | 599 (9.80) | 1,473 (89.16) | 179 (10.84) | 5,205 (85.17) | 906 (14.83) | 1,423 (86.14) | 229 (13.86) |
| Grade | ||||||||
| 1 | 31,000 (96.65) | 1,075 (3.35) | 188 (92.61) | 15 (7.39) | 29,105 (90.74) | 2,970 (9.26) | 187 (92.12) | 16 (7.88) |
| 2 | 34,854 (92.52) | 2,816 (7.48) | 1,973 (94.00) | 126 (6.00) | 32,255 (85.63) | 5,415 (14.37) | 1,881 (89.61) | 218 (10.39) |
| ≥ 3 | 9,785 (86.01) | 1,592 (13.99) | 6,101 (87.39) | 880 (12.61) | 9,464 (83.19) | 1,913 (16.81) | 6,217 (89.06) | 764 (10.94) |
| Tumor location | ||||||||
| Upper inner quadrant | 12,196 (93.38) | 864 (6.62) | 1,337 (88.66) | 171 (11.34) | 12,038 (92.17) | 1,022 (7.83) | 1,408 (93.37) | 100 (6.63) |
| Lower inner quadrant | 4,907 (94.29) | 297 (5.71) | 609 (89.17) | 74 (10.83) | 4,634 (89.05) | 570 (10.95) | 623 (91.22) | 60 (8.78) |
| Upper outer quadrant | 29,110 (93.17) | 2,135 (6.83) | 3,271 (87.76) | 456 (12.24) | 26,838 (85.9) | 4,407 (14.10) | 3,234 (86.77) | 493 (13.23) |
| Lower outer quadrant | 5,702 (92.73) | 447 (7.27) | 606 (91.27) | 58 (8.73) | 5,252 (85.41) | 897 (14.59) | 605 (91.11) | 59 (8.89) |
| Axillary tail | 292 (94.19) | 18 (5.81) | NR | NR | 254 (81.94) | 56 (18.06) | NR | NR |
| Nipple/central portion | 2,461 (91.01) | 243 (8.99) | 215 (93.48) | 15 (6.52) | 2,192 (81.07) | 512 (18.93) | 196 (85.22) | 34 (14.78) |
| Overlapping/NOS | 20,971 (93.41) | 1,479 (6.59) | 2,184 (89.91) | 245 (10.09) | 19,616 (87.38) | 2,834 (12.62) | 2,186 (90.00) | 243 (10.00) |
| Race/ethnicity | ||||||||
| White | 64,000 (93.59) | 4,385 (6.41) | 6,025 (89.63) | 697 (10.37) | 59,973 (87.70) | 8,412 (12.30) | 6,028 (89.68) | 694 (10.32) |
| Hispanic | 3,080 (90.94) | 307 (9.06) | 361 (84.74) | 65 (15.26) | 2,825 (83.41) | 562 (16.59) | 363 (85.21) | 63 (14.79) |
| Black | 6,188 (91.55) | 571 (8.45) | 1,670 (88.27) | 222 (11.73) | 5,735 (84.85) | 1,024 (15.15) | 1,675 (88.53) | 217 (11.47) |
| Other | 2,371 (91.51) | 220 (8.49) | 206 (84.77) | 37 (15.23) | 2,291 (88.42) | 300 (11.58) | 219 (90.12) | 24 (9.88) |
| Charlson Comorbidity Index | ||||||||
| 0 | 62,373 (93.34) | 4,450 (6.66) | 6,595 (89.11) | 806 (10.89) | 58,410 (87.41) | 8,413 (12.59) | 6,610 (89.31) | 791 (10.69) |
| 1 | 10,584 (93.05) | 790 (6.95) | 1,309 (89.11) | 160 (10.89) | 9,876 (86.83) | 1,498 (13.17) | 1,307 (88.97) | 162 (11.03) |
| ≥ 2 | 2,682 (91.69) | 243 (8.31) | 358 (86.68) | 55 (13.32) | 2,538 (86.77) | 387 (13.23) | 368 (89.10) | 45 (10.90) |
| Number of nodes examined | ||||||||
| 1 | 21,258 (92.25) | 1,786 (7.75) | 2,258 (94.75) | 125 (5.25) | ||||
| 2–3 | 33,296 (89.50) | 3,906 (10.50) | 3,944 (92.65) | 313 (7.35) | ||||
| 4–5 | 10,859 (86.85) | 1,644 (13.15) | 1,373 (88.98) | 170 (11.02) | ||||
| ≥ 6 | 5,411 (64.62) | 2,962 (35.38) | 710 (64.55) | 390 (35.45) | ||||
HR hormone receptor, TTS time to surgery, NOS not otherwise specified, NR not reportable